Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple Negative Breast Cancer: early-phase trial registry
68 of 119 indexed Triple Negative Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #105 of 28,707 conditions by registered trial count.
119 US clinical trials · 68 currently recruiting · #105 of 28,707 conditions by registered trial count
Triple Negative Breast Cancer: 119 US clinical trials tracked, 68 recruiting.
Triple Negative Breast Cancer is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 6 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-cancer
OPEN 68 | RECR 57% | LATE 8 | EARLY 98 | RANK #105 | SPON 6
Volume-matched condition peers
Nearest open-share peer: ACL (57% recruiting · 7 trials)
Triple Negative Breast Cancer lists 68 open slots (57% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple Negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple Negative Breast Cancer is recruiting above its size-band peers.
68 of 119 indexed trials (57.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Triple Negative Breast Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 6 of 119 trials (5%). 91 distinct sponsors appear on at least one study for this condition label.
-
Typical Triple Negative Breast Cancer enrolment sits around 77 participants.
Median target enrolment is 77 among the 119 trials that report a genuine target (sentinel values excluded). 67 of those (56.3%) plan for fewer than 100 participants.
-
Triple Negative Breast Cancer research is mostly interventional.
112 interventional and 7 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
119 total, page 3 of 3
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche
NCT02425891
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT04332653
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis Pharmaceuticals
NCT01351103
Phase II ABT-888 With Cyclophosphamide
National Cancer Institute (NCI)
NCT01306032
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Mundipharma Research Limited
NCT03345485
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
NCT02247037
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
TransThera Sciences (Nanjing)
NCT03654547
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
NCT01451632
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Curis
NCT02307240
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT02768701
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
Emotions Immunology and Breast Cancer
Luz A. Venta, MD
NCT03609671
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Columbia University
NCT00998036
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01818063
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Pure Biologics S.A.
NCT06273852
cMet CAR RNA T Cells Targeting Breast Cancer
University of Pennsylvania
NCT01837602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 70 |
| Phase 2 | 28 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple Negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple Negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple Negative Breast Cancer page
119 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 Triple Negative Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Triple Negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple Negative Breast Cancer condition card totals 119 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.